We are live on ! Find out more
PETX

Aratana Therapeutics
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

98 hedge funds and large institutions have $146M invested in Aratana Therapeutics in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 32 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 32

3.37% less ownership

Funds ownership: 76.88% → 73.5% (-3.4%)

8% less funds holding

Funds holding: 107 → 98 (-9)

17% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 18

32% less capital inflows, than outflows

Capital inflows: $13.5M | Capital outflows: $19.8M

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

93% less call options, than puts

Call options by funds: $310K | Put options by funds: $4.5M

Holders
98
Holders Change
-9
Holders Change %
-8.41%
% of All Funds
2.43%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
15
Increased
33
Reduced
32
Closed
18
Calls
$310​K
Puts
$4.5​M
Net Calls
-⁠$4.2​M
Net Calls Change
-⁠$4.06​M

PETX Hedge Fund Activity: Q1 2017 in Review

98 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics (PETX) for Q1 2017, worth a combined $146M — down 28% from $204M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of PETX and 15 opened new positions — a net loss of 3 holders — while 32 trimmed existing stakes and 33 added.

The largest buyer was Susquehanna International Group, adding an estimated $3.76M. The largest seller was First Light Asset Management, exiting entirely with an estimated $2.94M sold.

  • 98 institutional investors held Aratana Therapeutics (PETX) as of Q1 2017, down from 107 in Q4 2016.
  • Funds reported $146M of Aratana Therapeutics stock for Q1 2017, down 28% quarter-over-quarter.
  • 15 funds opened new Aratana Therapeutics positions in Q1 2017 and 18 closed out, a net change of -3 holders.
  • The largest Aratana Therapeutics buyer in Q1 2017 was Susquehanna International Group, an estimated $3.76M added.
  • The largest Aratana Therapeutics seller in Q1 2017 was First Light Asset Management, an estimated $2.94M sold.

Based on aggregated 13F filings for Q1 2017.